Other equities analysts also recently issued reports about the company. J P Morgan Chase & Co restated a neutral rating on shares of MorphoSys AG in a research note on Monday, July 17th. Commerzbank Ag set a €76.00 ($89.41) target price on MorphoSys AG and gave the stock a buy rating in a report on Tuesday, May 30th. HSBC Holdings plc set a €59.00 ($69.41) target price on MorphoSys AG and gave the stock a neutral rating in a report on Friday, July 14th. Berenberg Bank set a €68.00 ($80.00) target price on MorphoSys AG and gave the stock a buy rating in a report on Friday, July 14th. Finally, Independent Research GmbH set a €77.00 ($90.59) price target on MorphoSys AG and gave the company a buy rating in a report on Monday, July 17th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of €69.57 ($81.85).
MorphoSys AG (MOR) opened at 56.121 on Monday. MorphoSys AG has a 12-month low of €35.72 and a 12-month high of €70.90. The stock’s market capitalization is €1.63 billion. The company has a 50-day moving average price of €62.01 and a 200-day moving average price of €57.64.
About MorphoSys AG
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
What are top analysts saying about MorphoSys AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MorphoSys AG and related companies.